Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2024 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
Confirmed Presenting Companies:
Speaker Profile
Biography
Dr. Martin Stumpe serves as the Chief of AI at Tempus, where he leads the development of AI algorithms from NGS and digital pathology to improve clinical context and decision making for better patient care. Prior to Tempus, Dr. Stumpe founded and led the Cancer Pathology project at Google, which uses artificial intelligence to increase the accuracy in image based cancer detection and grading. Earlier in his career, Dr. Stumpe was part of the Kepler team at NASA Ames Research Center; and before that, he was a postdoctoral researcher at Stanford University focusing on molecular dynamics simulations to study chaperone induced protein folding. Dr. Stumpe holds a PhD in Computational and Theoretical Physics from the Max Planck Institute for Biophysical Chemistry in Goettingen, Germany.
AI and Data Sciences Showcase:
Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, Tempus enables physicians to deliver personalized patient care and accelerates the development of optimal therapeutics.
Speaker Profile
Biography
Ben builds computational tools that make life science research faster, more productive, more social and more fun. As a leader of artificial intelligence research and development at Rosalind, Inc., he is currently laying the foundation for trustworthy and accountable generative A.I. services meant to assist scientists at every phase of the research cycle. Prior to joining Rosalind, Ben spent much of his career advancing systems that facilitate the collaborative creation of collective intelligence in biology including: the Gene Wiki, Wikidata, CIViC, and the Gene Ontology Initiative. He has published more than 80 scientific articles in domains ranging from machine learning to games with a scientific purpose.
AI and Data Sciences Showcase:
Rosalind
ROSALIND is the leading collaborative research platform for knowledge management and multi-omic data analysis. As a secure unified data hub for sequencing and multiplex technologies, ROSALIND combines deep interpretation and interactive visualization for spatial, single-cell, RNA, NanoString, and clinical data.
Speaker Profile
Biography
Arnout Van Hyftes journey with BioStrand, now a subsidiary of IPA (ImmunoPrecise Antibodies), began in 2019 as a key member of the founding team. He has played a pivotal role in shaping the company's commercial strategies, setting the stage for its remarkable growth, and building a robust infrastructure that forms the very foundation of BioStrand's operations. Arnout oversees the development team, ensuring their seamless coordination and fostering a culture of innovation. His leadership extends to crafting effective sales and marketing strategies, as well as engaging with the market to cultivate meaningful relationships.
AI and Data Sciences Showcase:
ImmunoPrecise (IPA)
ImmunoPrecise is a biotherapeutic research hub leveraging systems biology, multiomics modeling and complex artificial intelligence systems to support its proprietary antibody discovery technologies. Combining an AI driven approach with best-in-class laboratory capabilities creates a powerful synergy that is revolutionizing antibody discovery.
Speaker Profile
Biography
Physician, epidemiologist, biomedical engineer, scientist, and entrepreneur, dedicated to optimizing healthcare by translating clinical needs into technical solutions. Previously, led the clinical cardiovascular imaging research group at Stanford Radiology.His clinical and research background allows to identify and address medical shortcomings effectively. Beyond his technical expertise, he has leadership with various international scientific organizations and co-directs educational courses. With over 100 peer-reviewed papers published, 30 international lectures presented, and funding received from prestigious entities, he holds the title of Fellow of the Society of Cardiovascular Computed Tomography (SCCT). His work, acknowledged through numerous awards, reflects significant contributions to the fields of radiology and cardiovascular imaging.
AI and Data Sciences Showcase:
Segmed, Inc.
Segmed aims to transform healthcare research by extracting valuable information from medical imaging studies for innovative applications. Our platform facilitates global cohort identification, secure extraction, de-identification, and transfer of targeted studies. Linking images to clinical data support research, AI-imaging, disease diagnosis, and treatment.
Speaker Profile
Biography
Tim leads Solve M.E.s data, AI, and research strategy to advance precision medicine for MECFS, Long COVID, and other post-infection diseases. He is an author and reviewer for the JCO Clinical Cancer Informatics and a member of the NINDS MECFS Biospecimen Resource Access Committee. Previously, Tim oversaw research funding at both the American Society for Radiation Oncology and the NIH. He has been recognized by awards such as the NIH Directors Award, NCATS Directors Award, NIAID Merit Award, the U.S. Department of State Embassy Science Fellowship, and the American Association for the Advancement of Science (AAAS) Science and Technology Policy Fellowship.
Talk
RWD to Advance Precision Medicine for Post-Acute Infection Syndromes.
After the concept and architecture of Solve M.E.'s RWD strategy and platform are introduced, case studies will demonstrate how RWD advanced patient subtyping, personalized analytics, hypothesis generation, and clinical trial recruitment. Future plans to leverage AIML, digital biomarkers, and digital twin to further catalyze precision medicine research will also be discussed.
AI and Data Sciences Showcase:
Solve M.E.
The Solve ME/CFS Initiative (Solve M.E.) is a non-profit organization that serves as a catalyst for critical research into diagnostics, treatments, and cures for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long Covid and other post-infection diseases.
Speaker Profile
Biography
Backed by his expertise in molecular diagnostics, molecularly targeted drug discovery and development, biochemistry and regulatory compliance, Rob Fraser drives the innovation behind Molecular Yous multi-omic AI-powered analytics platform. Under his direction, Molecular You has established an affordable, comprehensive method of measuring hundreds of biomarkers from a single blood sample, and a LLM and ML model to incorporate the worlds leading scientific literature and collected data to accurately predict individual and population health risks.Previously, as the Chief Operating Officer of the Personalized Medicine Initiative, Rob supported the establishment of six new companies including Molecular You. Rob has also been involved in leading drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD.
AI and Data Sciences Showcase:
Molecular You
Molecular You is the first and only multi-biomarker analytics platform, providing decision support to clinicians and ACOs based on highly accurate predictive risk profiles in 26+ health areas.
Speaker Profile
Biography
Gwenn Berry is the founding engineer and CEO of Magna Labs Inc., whose mission is to accelerate the innovation and delivery of precision science medicine by empowering scientists to build and test high-quality bioinformatics tools. Gwenn has over a decade of experience in applying and adapting software best practices to bioinformatics algorithm development and transitioning research software into both commercial research-use-only (RUO) and in-vitro diagnostic (IVD) on-market products in the genomics industry. Her work specializes in production-grade bioinformatics algorithm and pipeline development, including methods evaluation and optimization, novel methods development, verification and validation, and remediation of prototype or research-grade software for commercial and clinical readiness.
Talk
Automating bioinformatic software validation for production-grade development
Bioinformatics software drives omics research and development, yet comprehensive software QA is often ad hoc, manual and time-intensive. Miqa, a no-code, cloud-enabled QA automation platform, continuously tests and benchmarks bioinformatic algorithms, ensuring development speed, analytical accuracy, and data reproducibility to transform genomic information into actionable insights for precision medicine.
AI and Data Sciences Showcase:
Magna Labs
Magna Labs provides software quality assurance (QA) solutions to support the safe development and evaluation of bioinformatic software for precision therapeutics and diagnostics. Our software tools help scientists easily incorporate software testing best practices into their workflows, improving the quality and speed of scientific innovations.
Speaker Profile
Biography
Vasu Rangadass, Ph.D., is the CEO of L7 Informatics, a company that delivers software and services enabling DATA+INTELLIGENCE for science and health. Since joining L7, Dr. Rangadass has led the further development of the Enterprise Science Platform (L7ESP), a cutting-edge scientific process and data management solution that empowers life science and healthcare organizations to connect people, processes, and systems, accelerating discoveries and advancing precision healthcare.Prior to L7 Informatics, Dr. Rangadass served as Chief Strategy Officer at NantHealth, following its acquisition of Net.Orange, the company he founded. Net.Orange provided an enterprise-wide platform, the Clinical Operating System (cOS), designed to simplify and optimize care delivery processes within health systems. With a rich background in digital health and a passion for transforming healthcare through innovative technology, Dr. Rangadass continues to lead initiatives that drive impactful change in the industry.
Talk
Accelerating Precision Medicine with Unified Platforms
Discover how L7ESP transforms precision medicine by offering data contextualization at the point of execution. Learn how this capability supports successful AI integration, enhances efficiency, and drives rapid breakthroughs. Optimize your approach to drug development and personalized treatments with advanced data orchestration and contextualization.
AI and Data Sciences Showcase:
L7 Informatics, Inc.
L7 Informatics, Inc. is a leading provider of integrated scientific data and analytics solutions. The company offers a comprehensive platform that enables seamless data integration, advanced analytics, and collaborative workflows, empowering scientists and researchers to accelerate discoveries, improve operational efficiencies, and drive innovation.
Speaker Profile
Biography
Rachel Gollub founded her current company to bring together patient medical history, social determinants of health, and genomic data to bring secure precision medicine to patients everywhere. A Silicon Valley inventor and entrepreneur with a degree from Caltech, she started her career on the team inventing the Java language, later moving to Stanford University to design and build the Stanford Digital Repository. Since then, she has been founding companies to leverage the latest technologies. Most recently, she left a position as CTO of the UnitedHealthcare Technology Employer Individual division to leverage her AI and machine learning background to build a startup at the heart of precision medicine.
Talk
Precision Medicine through Reinforcement Learning
PointHealth AI uses reinforcement learning to bring together several aspects of patient data to determine the best course of treatment for a specific patient at the point of diagnosis. Here's how we do it.
AI and Data Sciences Showcase:
PointHealth AI
PointHealth AI brings together medical history, social determinants of health, and genomics to bring better courses of treatment to patients. We give providers on-the-spot recommendations from our data analyses to help patients at the point of diagnosis.
Speaker Profile
Biography
AI and Data Sciences Showcase:
Prism AI
Speaker Profile
Biography
Matthew Albert is currently at Octant Bio, where he focuses on integrating translational medicine and innovative approaches to drug discovery and development. His work centers on harnessing advanced biomarker strategies, human genetics and functional genomics-driven insights to address rare diseases, with a commitment to making personalized medicine a reality. At Octant, Matthew collaborates across scientific disciplines, aiming to transform therapeutic approaches by combining small molecule corrector therapies with cutting-edge platform technologies. He leverages his extensive experience in human genetics and translational research to guide teams in developing next-generation therapies. Matthew's vision is anchored in the belief that accelerated innovation and personalized solutions are key to addressing unmet medical needs.
Talk
Unlocking Human Genetics for Precision Clinical Trials
At Octant Bio, we leverage deep mutational scans and genetic data to develop targeted small molecule therapies. By defining mechanistic insight into response to corrector therapy, we optimize strategies that advance precision medicine for genetic disorders. Our lead program focuses on Rhodopsin-associated Retinitis Pigmentosa (RHO-adRP), providing hope for approximately 50% of patients with amenable mutations.
Large-scale Data Solutions Showcase:
Octant Bio
Octant Bio is a biotechnology company using cutting-edge technologies to develop precision medicines. By combining synthetic biology, data-driven insights, and nano-scale high-throughput chemical screens, Octant is transforming drug discovery with the aim to improve patient outcomes across multiple therapeutic areas.
Speaker Profile
Biography
Dr. Kira Radinsky is an accomplished computer scientist, entrepreneur, and keynote speaker. She was born in Ukraine in 1986 and moved with her family to Israel at the age of four. Radinsky showed an early aptitude for mathematics and computer science, and by the age of 16, she was studying at the Technion - Israel Institute of Technology. She was awarded the prestigious Google Europe Fellowship in Social Computing for her groundbreaking work in data mining and natural language processing and founded SalesPredict, a predictive analytics startup that uses machine learning algorithms to help businesses forecast future sales. The company was acquired by eBay in 2016, and Radinsky continued to work with eBay as its director of data science until 2017. She has since founded Diagnostic Robotics, a healthcare analytics solution company focused on using machine learning and other advanced technologies to make healthcare more efficient, effective, and accessible.
Talk
Advancing Ethical AI in Proactive Care
Care providers are constantly asked to do more with less. Carefully and thoughtfully using the latest in predictive analytics, and combining that with tools that automate manual processes (such as data mining, outreach prioritization, and information gathering) can help bring joy back to working in healthcare, address staffing challenges, and make care more proactive.
AI and Data Sciences Showcase:
Diagnostic Robotics
Diagnostic Robotics exists to bring trusted, leading edge, proactive analytics and tools to healthcare. We’re a clinician’s trusted resource to relieve administrative burdens, improve staffing ratios, reduce cost of care, and improve patient experiences.
Speaker Profile
Biography
Tom Neyarapally is the CEO Co-Founder of Archetype Therapeutics, an AI-native company pioneering the use of generative chemogenomics in patient data-driven drug discovery and repurposing in cancer and other diseases. The Archetype platform enables virtual phenotypic screening of billions of molecules per day for their effect on clinical outcomes in cohorts of patients with unmet medical need. Previously Tom was CCO and founding team member at Sema4, a patient-centered health intelligence and genetic testing company. He was also a member of the founding team and Executive Vice President, Corporate Development at the causal AI drug discovery company Aitia. After graduate school, Tom served as a corporate and IP lawyer at Chadbourne Parke LLP and Frommer Lawrence Haug LLP. He started his career as an analyst focused on pharmaceuticals at the management consulting firm Arthur D. Little.
Talk
Diagnostics Driven Drug Discovery Using Generative Chemogenomics
Validated clinical genomic tests built using real world outcome data effectively predict poor patient outcomes. Generative chemogenomics virtually tests billions of compounds abilities to reverse the molecular fate of patients with poor predicted outcomes. New drug candidates and insights into existing drug programs are generated without waiting years for outcomes.
AI and Data Sciences Showcase:
Archetype Therapeutics
Archetype Therapeutics is an AI-native biotech company that is with its Archetype™ platform pioneering the use of generative chemogenomics and patient clinicogenomic data to enable the virtual screening of billions of potential drugs per day.
Speaker Profile
Biography
aJoseph Mossel is CEO and Co-Founder of Ibex Medical Analytics. Together with Co-Founder and CTO Chaim Linhart, he embarked on a journey to transform cancer diagnostics by empowering pathologists with AI insights that help them improve diagnostic accuracy, efficiency and turnaround times. His career in the tech industry spans more than 20 years, starting off in software development and product management followed with leadership positions in startups and large multinational corporations where he has led products from inception all the way to maturity as multi-million-dollar businesses. Joseph has also held a tenure in the non-profit sector, serving as managing director of Israels National Ecosystem Assessment Program.Joseph holds an MSc in computer science from Tel Aviv University, and an MSc in environmental science from VU Amsterdam. He is an alumnus of the Adi Lautman Interdisciplinary Program for Outstanding Students at Tel Aviv University.
Talk
AI in Cancer Diagnostics: Real World Learnings
Ibex Medical Analytics is transforming cancer diagnostics with clinical grade AI-powered solutions for pathology. Deployed globally in routine clinical use, this session will cover key learnings from Ibexs vast customer usage, strategic industry partnerships and collaboration with pharmaceutical and biotechnology companies to enable precision medicine.
AI and Data Sciences Showcase:
Ibex Medical Analytics
Ibex Medical Analytics is transforming cancer diagnostics with clinical grade AI powered solutions for pathology. Empowering clinicians and pathologists, Ibex strives to provide accurate, timely and personalized cancer diagnosis for every patient. Ibex is the first and most widely deployed AI-powered platform in pathology.